中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

病原感染在自身免疫性肝病发生发展中的作用

张海萍 闫惠平 陈德喜 马迎民

引用本文:
Citation:

病原感染在自身免疫性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2022.04.004
基金项目: 

北京市属医学科研院所公益发展改革试点项目 (Jingyiyan 2021-10)

首都医科大学附属北京佑安医院2021年院内中青年人才孵育项目(青年创新类) (YNKTQN2021004)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:张海萍负责收集资料分析并撰写论文;闫惠平负责写作设计、思路指导及论文修改并最后定稿;陈德喜和马迎民负责论文审阅。
详细信息
    通信作者:

    闫惠平,yhp503@126.com

The role of pathogen infections in the development and progression of autoimmune liver diseases

Research funding: 

Pilot Project of Public Welfare Development and Reform of Beijing Municipal Medical Research Institutes (Jingyiyan 2021-10);

Young and Middle-aged Talent Incubation Project in the Hospital of Beijing YouAn Hospital, Capital Medical University, 2021 (Youth Innovation) (YNKTQN2021004)

More Information
    Corresponding author: YAN Huipng, yhp503@126.com(ORCID: 0000-0002-1787-0067)
  • 摘要: 自身免疫性肝病(AILD)的病因和发病机制研究一直是领域内的研究热点。病原体感染可参与诱发机体的自身免疫反应,常常成为免疫性疾病的关键致病因素。本文基于文献数据和作者临床经验,将从分子模拟机制等方面对病原感染在AILD的发生和发展中的作用及其影响进行简单介绍,以助更深入地了解AILD的发病机制。

     

  • 表  1  人PDC-E2 155-1851*的分子模拟和免疫优势表位

    Table  1.   Molecular mimicry and immunodominant epitopes of human PDC-E2 155-1851*

    人类PDC-E2 KVGEKLSEGDLLAEIETDK*ATIGFEVQEEGY
    B淋巴细胞 KVGEKLSEGDLLAEIETDK*ATIGFEVQEEGY
    CD4+T淋巴细胞 KVGEKLSEGDLLAEIETDK*ATIGFEVQEEGY
    CD8+T淋巴细胞 KVGEKLSEGDLLAEIETDK*ATIGFEVQEEGY
    E. coli PDC-E2 2** K-G-----L-EIETDK-----G-
    Novosphingobium aromaticivorans -----GD-LAEIETDKAT--FE---EG-
    PDC-E2
    注: *K为硫辛酸的附着位点173lysine(赖氮酸);横线部分为每种细胞识别的表位;* * ExDK序列存在于人源和大肠杆菌PDC-E2中。
    下载: 导出CSV
  • [1] CZAJA AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions[J]. World J Gastroenterol, 2019, 25(45): 6579-6606. DOI: 10.3748/wjg.v25.i45.6579.
    [2] TANAKA A, LEUNG P, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195(1): 25-34. DOI: 10.1111/cei.13198.
    [3] ROWLEY D, JENKIN CR. Antigenic cross-reaction between host and parasite as a possible cause of pathogenicity[J]. Nature, 1962, 193: 151-154. DOI: 10.1038/193151a0.
    [4] DAMIAN RT. Molecular mimicry in biological adaptation[J]. Science, 1965, 147(3660): 824. DOI: 10.1126/science.147.3660.824-b.
    [5] FLOREANI A, LEUNG PS, GERSHWIN ME. Environmental basis of autoimmunity[J]. Clin Rev Allergy Immunol, 2016, 50(3): 287-300. DOI: 10.1007/s12016-015-8493-8.
    [6] AGMON-LEVIN N, PAZ Z, ISRAELI E, et al. Vaccines and autoimmunity[J]. Nat Rev Rheumatol, 2009, 5(11): 648-652. DOI: 10.1038/nrrheum.2009.196.
    [7] ANG CW, JACOBS BC, LAMAN JD. The Guillain-Barré syndrome: A true case of molecular mimicry[J]. Trends Immunol, 2004, 25(2): 61-66. DOI: 10.1016/j.it.2003.12.004.
    [8] KOGA M, GILBERT M, LI J, et al. Complex of GM1- and GD1a-like lipo-oligosaccharide mimics GM1b, inducing anti-GM1b antibodies[J]. PLoS One, 2015, 10(4): e0124004. DOI: 10.1371/journal.pone.0124004.
    [9] KIRVAN CA, GALVIN JE, HILT S, et al. Identification of streptococcal m-protein cardiopathogenic epitopes in experimental autoimmune valvulitis[J]. J Cardiovasc Transl Res, 2014, 7(2): 172-181. DOI: 10.1007/s12265-013-9526-4.
    [10] ZHANG Y, XIAO M, ZHANG S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19[J]. N Engl J Med, 2020, 382(17): e38. DOI: 10.1056/NEJMc2007575.
    [11] MIELI-VERGANI G, VERGANI D, CZAJA AJ, et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4: 18017. DOI: 10.1038/nrdp.2018.17.
    [12] MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
    [13] ZACHOU K, RIGOPOULOU E, DALEKOS GN. Autoantibodies and autoantigens in autoimmune hepatitis: Important tools in clinical practice and to study pathogenesis of the disease[J]. J Autoimmune Dis, 2004, 1(1): 2. DOI: 10.1186/1740-2557-1-2.
    [14] FERRI S, MURATORI L, LENZI M, et al. HCV and autoimmunity[J]. Curr Pharm Des, 2008, 14(17): 1678-1685. DOI: 10.2174/138161208784746824.
    [15] MURATORI P, MURATORI L, VERUCCHI G, et al. Non-organ-specific autoantibodies in children with chronic hepatitis C: Clinical significance and impact on interferon treatment[J]. Clin Infect Dis, 2003, 37(10): 1320-1326. DOI: 10.1086/379018.
    [16] HAN Y, YAN HP, LIAO HY, et al. Clinical value of anti-liver/kidney microsomal-1 antibody in patients with liver disease[J]. Chin J Hepatol, 2017, 25(11): 852-857. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.010.

    韩莹, 闫惠平, 廖慧钰, 等. 抗肝肾微粒体抗体在肝病患者中的临床意义评价[J]. 中华肝脏病杂志, 2017, 25(11): 852-857. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.010.
    [17] MARCEAU G, LAPIERRE P, BÉLAND K, et al. LKM1 autoantibodies in chronic hepatitis C infection: A case of molecular mimicry?[J]. Hepatology, 2005, 42(3): 675-682. DOI: 10.1002/hep.20816.
    [18] FERRI S, MURATORI L, QUARNETI C, et al. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C[J]. J Hepatol, 2009, 50(6): 1093-1101. DOI: 10.1016/j.jhep.2009.02.020.
    [19] GREGORIO GV, CHOUDHURI K, MA Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection[J]. Clin Exp Immunol, 2003, 133(3): 404-413. DOI: 10.1046/j.1365-2249.2003.02229.x.
    [20] VENTO S, GAROFANO T, DI PERRI G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals[J]. Lancet, 1991, 337(8751): 1183-1187. DOI: 10.1016/0140-6736(91)92858-y.
    [21] YAN HP, JIA JD. Autoimmune liver disease[M]. Beijing: People's Medical Publishing House, 2018.

    闫惠平, 贾继东. 自身免疫性肝脏疾病[M]. 北京: 人民卫生出版社, 2018.
    [22] RIGOPOULOU EI, SMYK DS, MATTHEWS CE, et al. Epstein-barr virus as a trigger of autoimmune liver diseases[J]. Adv Virol, 2012, 2012: 987471. DOI: 10.1155/2012/987471.
    [23] CHRISTEN U, HINTERMANN E. Pathogens and autoimmune hepatitis[J]. Clin Exp Immunol, 2019, 195(1): 35-51. DOI: 10.1111/cei.13203.
    [24] ZELLOS A, SPOULOU V, ROMA-GIANNIKOU E, et al. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: Art of facts or an artifact?[J]. Ann Hepatol, 2013, 12(1): 147-151.
    [25] MANNS MP, GRIFFIN KJ, SULLIVAN KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450ⅡD6, a cytochrome P-450 monooxygenase[J]. J Clin Invest, 1991, 88(4): 1370-1378. DOI: 10.1172/JCI115443.
    [26] HAGEL S, BRUNS T, HERRMANN A, et al. Autoimmune hepatitis in an HIV-infected patient: An intriguing association[J]. Int J STD AIDS, 2012, 23(6): 448-450. DOI: 10.1258/ijsa.2009.009337.
    [27] FLOREANI A, LEUNG PS, GERSHWIN ME. Environmental basis of autoimmunity[J]. Clin Rev Allergy Immunol, 2016, 50(3): 287-300. DOI: 10.1007/s12016-015-8493-8.
    [28] BURROUGHS AK, ROSENSTEIN IJ, EPSTEIN O, et al. Bacteriuria and primary biliary cirrhosis[J]. Gut, 1984, 25(2): 133-137. DOI: 10.1136/gut.25.2.133.
    [29] FLOREANI A, BASSENDINE MF, MITCHISON H, et al. No specific association between primary biliary cirrhosis and bacteriuria?[J]. J Hepatol, 1989, 8(2): 201-207. DOI: 10.1016/0168-8278(89)90008-1.
    [30] CORPECHOT C, CHRÉTIEN Y, CHAZOUILLÈRES O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis[J]. J Hepatol, 2010, 53(1): 162-169. DOI: 10.1016/j.jhep.2010.02.019.
    [31] GERSHWIN ME, SELMI C, WORMAN HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients[J]. Hepatology, 2005, 42(5): 1194-1202. DOI: 10.1002/hep.20907.
    [32] PARIKH-PATEL A, GOLD EB, WORMAN H, et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states[J]. Hepatology, 2001, 33(1): 16-21. DOI: 10.1053/jhep.2001.21165.
    [33] PRINCE MI, DUCKER SJ, JAMES OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations[J]. Gut, 2010, 59(4): 508-512. DOI: 10.1136/gut.2009.184218.
    [34] CORPECHOT C, CHRÉTIEN Y, CHAZOUILLÈRES O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis[J]. J Hepatol, 2010, 53(1): 162-169. DOI: 10.1016/j.jhep.2010.02.019.
    [35] SHIMODA S, HARADA K, NIIRO H, et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis[J]. Hepatology, 2011, 53(4): 1270-1281. DOI: 10.1002/hep.24194.
    [36] BJÖRKLAND A, FESTIN R, MENDEL-HARTVIG I, et al. Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer cells and recruitment of primed memory T cells[J]. Hepatology, 1991, 13(6): 1106-1111. DOI: 10.1002/hep.1840130617.
    [37] van de WATER J, ANSARI A, PRINDIVILLE T, et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis[J]. J Exp Med, 1995, 181(2): 723-733. DOI: 10.1084/jem.181.2.723.
    [38] FREDRICKSON JK, BALKWILL DL, DRAKE GR, et al. Aromatic-degrading Sphingomonas isolates from the deep subsurface[J]. Appl Environ Microbiol, 1995, 61(5): 1917-1922. DOI: 10.1128/aem.61.5.1917-1922.1995.
    [39] TAKEUCHI M, HAMANA K, HIRAISHI A. Proposal of the genus Sphingomonas sensu stricto and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of phylogenetic and chemotaxonomic analyses[J]. Int J Syst Evol Microbiol, 2001, 51(Pt 4): 1405-1417. DOI: 10.1099/00207713-51-4-1405.
    [40] MANFREDO VIEIRA S, HILTENSPERGER M, KUMAR V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359(6380): 1156-1161. DOI: 10.1126/science.aar7201.
  • 加载中
表(1)
计量
  • 文章访问数:  425
  • HTML全文浏览量:  138
  • PDF下载量:  92
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-04
  • 录用日期:  2022-02-17
  • 出版日期:  2022-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回